Aficamten for Drug-Refractory Severe Obstructive Hypertrophic Cardiomyopathy in Patients Receiving Disopyramide: REDWOOD-HCM Cohort 3-Reference-Cited by-同舟云学术

Aficamten for Drug-Refractory Severe Obstructive Hypertrophic Cardiomyopathy in Patients Receiving Disopyramide: REDWOOD-HCM Cohort 3

Published:2023-07 Issue: Volume: Page:
ISSN:1071-9164
Container-title:Journal of Cardiac Failure
language:en
Short-container-title:Journal of Cardiac Failure

Author:

OWENS ANJALI T.,MASRI AHMAD^ORCID,ABRAHAM THEODORE P.,CHOUDHURY LUBNA,RADER FLORIAN,SYMANSKI JOHN D.,TURER ASLAN T.,WONG TIMOTHY C.,TOWER-RADER ALBREE,COATS CAROLINE J.,FIFER MICHAEL A.,OLIVOTTO IACOPO,SOLOMON SCOTT D.,WATKINS HUGH C.,HEITNER STEPHEN B.,JACOBY DANIEL L.,KUPFER STUART,MALIK FADY I.,MENG LISA,SOHN REGINA,WOHLTMAN AMY,MARON MARTIN S.

Funder

Cytokinetics

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference5 articles.

1. Multicenter study of the efficacy and safety of disopyramide in obstructive hypertrophic cardiomyopathy;Sherrid;J Am Coll Cardiol,2005

2. Study design and rationale of EXPLORER-HCM: evaluation of mavacamten in adults with symptomatic obstructive hypertrophic cardiomyopathy;Ho;Circ Heart Fail,2020

3. CAMZYOSTM (mavacamten) capsules for oral use. Prescribing information; revised September 2022. Available at https://packageinserts.bms.com/pi/pi_camzyos.pdf. Accessed June 9, 2023. Bristol-Myers Squibb Company, Princeton, NJ, USA.

4. Phase 2 study of aficamten in patients with obstructive hypertrophic cardiomyopathy;Maron;J Am Coll Cardiol,2023

5. A phase 1 dose-escalation study of the cardiac myosin inhibitor aficamten in healthy participants;Malik;JACC Basic Transl Sci,2022

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Innovative pharmacological approaches to hypertrophic cardiomyopathy: The emerging role of Aficamten;Current Problems in Cardiology;2024-11

2. Pharmacokinetics, disposition, and biotransformation of the cardiac myosin inhibitor aficamten in humans;Pharmacology Research & Perspectives;2024-09-10

3. Aficamten and Cardiopulmonary Exercise Test Performance;JAMA Cardiology;2024-09-04

4. Effect of Aficamten on Health Status Outcomes in Obstructive Hypertrophic Cardiomyopathy;Journal of the American College of Cardiology;2024-09

5. Dosing and Safety Profile of Aficamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy: Results From SEQUOIA‐HCM;Journal of the American Heart Association;2024-08-06